• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MITOXANTRONE Drug Record

  • Summary
  • Interactions
  • Claims
  • MITOXANTRONE chembl:CHEMBL58 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    MITOXANTRONE
    NSC-279836
    MITOXANTRONE HCL
    NOVANTRONE
    CL-232315
    MITOXANTRONUM
    NOVANTRONEĀ®
    1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
    MITOXANTRONA
    pubchem.compound:4212
    drugbank:01204
    rxcui:7005
    chembl:CHEMBL58
    chemidplus:65271-80-9

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1987
    Drug Class Small molecule
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
    McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
    Brown et al., 1998, Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease., Am. J. Clin. Pathol.
    Ko et al., 2008, Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis., J. Neurol. Sci.
    Mao et al., 1999, Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity., Biochemistry
    Wang et al., 2001, Atp-bound topoisomerase ii as a target for antitumor drugs., J. Biol. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Takeda et al., 1998, A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide., Int. J. Hematol.
    Satherley et al., 2000, Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma., J. Pathol.
    Chi et al., 2001, A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer., Clin. Cancer Res.
    Wan X et al., 2013, A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling., J Med Chem
    List et al., 1996, Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia., Blood
    Kobylinska et al., 2004, Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells., Oncol. Rep.
    Rassidakis et al., 2002, BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome., Clin. Cancer Res.
    Parker et al., Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells., Cancer Biol. Ther.
    Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
    Burchell et al., 1990, The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells., Int. Symp. Princess Takamatsu Cancer Res. Fund
    Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
    Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics
  • MITOXANTRONE   C10ORF67

    Interaction Score: 3.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • MITOXANTRONE   GALNT14

    Interaction Score: 1.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31611591 21635146


    Sources:
    PharmGKB

  • MITOXANTRONE   RPSA

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8630412


    Sources:
    NCI

  • MITOXANTRONE   UGT1A5

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1966888


    Sources:
    NCI

  • MITOXANTRONE   TOP2A

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name liposome encapsulated mitoxantrone (LEM)
    Novel drug target Established target
    Trial Name mitoxantrone hydrochloride,Novantrone

    PMIDs:
    9494516 9426516 18687447 10451375 11278845 11752352 9631585 11004693


    Sources:
    TdgClinicalTrial NCI TEND

  • MITOXANTRONE   MBNL1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   DNMT1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12878861


    Sources:
    NCI

  • MITOXANTRONE   PIM1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23442188


    Sources:
    DTC

  • MITOXANTRONE   BAX

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14767525 11839668


    Sources:
    NCI

  • MITOXANTRONE   NSD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   ARSA

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   BCL2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11751483


    Sources:
    NCI

  • MITOXANTRONE   SLCO1B1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26663398


    Sources:
    PharmGKB

  • MITOXANTRONE   TOP2B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • MITOXANTRONE   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12684687


    Sources:
    NCI

  • MITOXANTRONE   ABCG2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • MITOXANTRONE   RACGAP1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   THPO

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   WRN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   RAD52

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   NFKB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   RGS4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   BLM

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   MPHOSPH8

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   MAPK1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   RECQL

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   POLH

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   HTT

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   FEN1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   YES1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   POLI

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   SMAD3

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • MITOXANTRONE   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   POLK

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   ATAD5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   KDM4A

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MITOXANTRONE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: MITOXANTRONE

    • Version: 01-August-2011

    Alternate Names:
    MITOXANTRONE Primary Drug Name

    Drug Info:
    Year of Approval 1987
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: MITOXANTRONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: MITOXANTRONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL58 ChEMBL Drug ID

    Drug Info:

    Publications:
    Wan X et al., 2013, A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling., J Med Chem

  • NCI: MITOXANTRONE

    • Version: 14-September-2017

    Alternate Names:
    C665 NCI drug code

    Drug Info:

    Publications:
    Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
    Parker et al., Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells., Cancer Biol. Ther.
    List et al., 1996, Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia., Blood

  • PharmGKB: mitoxantrone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
    Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics

  • TTD: Mitoxantrone

    • Version: 2020.06.01

    Alternate Names:
    D0R3JB TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL58

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21